IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.9600
+0.0372 (4.03%)
Apr 25, 2025, 4:00 PM EDT - Market closed
IO Biotech Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for IO Biotech stock have an average target of 9.33, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 871.88% from the current stock price of 0.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IO Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,150.00% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,150.00% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,150.00% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,150.00% | Nov 6, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +525.00% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
n/a
from 266.45M
Revenue Next Year
n/a
EPS This Year
-1.42
from -1.45
EPS Next Year
-1.15
from -1.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 48.8M | 137.5M | ||
| Avg | n/a | 17.1M | 77.2M | ||
| Low | n/a | n/a | 23.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 703.9% | ||
| Avg | - | - | 351.3% | ||
| Low | - | - | 39.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.23 | -0.92 | -0.70 | ||
| Avg | -1.42 | -1.15 | -0.75 | ||
| Low | -1.47 | -1.48 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.